


Open Pharma quarterly update: July–September 2020

This quarter saw the exciting launch of our four new Open Pharma workstreams: Workstream 1: Transparency; Workstream 2: Accountability; Workstream 3: Accessibility; and Workstream 4: Discoverability.

The Transparency working group have been busy running an automated analysis to assess the open access rates of pharma publications, with calls with our individual Member and Supporter companies to discuss our findings. The Accountability working group have been in discussions with the GPP4 committee about the inclusion of ORCID in the new guidelines. Together with the PFMD initiative, the Accessibility working group have been discussing how best to align their approach to developing a standardized format for plain language summaries. Finally, the Discoverability working group have been in conversation with Wiley about a project to investigate the effect of enhanced content on research impact.

Activities this quarter



Coming up

The Open Pharma team are preparing a number of activities and communications in the run-up to International Open Access Week 2020, including:

- 'Publishing open access saves lives' – NetworkPharma Zoom webinar consisting of a 5-minute presentation followed by a panel discussion on open access with different stakeholders in academic publishing. You can register for the event here: https://zoom.us/webinar/register/WN_ZCRDDi3uTYewj8UX1CwFqw
- An infographic celebrating 1 year since the launch of the Open Pharma position statement on open access (if you haven't already, please remember to endorse the position statement on the Open Pharma blog)

We are also developing two abstracts for submission to the 2021 European Meeting of ISMPP, supported by the working groups of our Members and Supporters for each workstream.

Oxford PharmaGenesis takes part in a number of activities revolving around open science to help Open Pharma gather insight and build a strong network of supporters; these activities go beyond the core Open Pharma plan and are carried out at no cost to Open Pharma.